AIM ImmunoTech Doses Final Patient In Phase 2 Trial Of Ampligen For Treatment Of Metastatic Pancreatic Cancer In Combination With AstraZeneca's Imfinzi; Topline Results Expected Q1 2027

Benzinga Newsdesk www.benzinga.com Positive 62.4%

Neg 0% Neu 0% Pos 62.4%

Comments

No comments yet. Be the first!